TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17984165
Drug: atorvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin alone
Study: 1961959
Drug: Thiopental, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental, 4 mg/kg
Study: 21876313
Drug: Low-dose MMF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MMF
Study: 12893374
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (1 ml) in the axillary plexus (TGr)
Study: 7744234
Drug: Insulin doses
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin doses
Study: 7744234
Drug: 24-h mean
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h mean serum insulin
Study: 7744234
Drug: 24-h mean
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h mean serum insulin and HbA1c concentration
Study: 7744234
Drug: Insulin values
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin values at 03.00 hours
Study: 7744234
Drug: Insulin values
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin values at 07.00 hours
Study: 7744234
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of insulin profiles
Study: 31155169
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1 μg/kg)
Study: 27977797
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine (3 or 4 doses)
Study: 24754047
Drug: G-CSF treatment
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF treatment (Group A)
Study: 22009649
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (Group B)
Study: 20854735
Drug: Xuebijing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection (100 ml once daily for 7 days)
Study: 15985478
Drug: Metyrapone (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (750 mg every 4 h for 24 h)
Study: 6958484
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 micrograms daily)
Study: 3881501
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (400 micrograms daily)
Study: 1642836
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin hydrochloride (250 mg/mL in saline solution, four drops administered locally twice a day for 5 to 10 days)
Study: 1642836
Drug: Intramuscular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gentamicin sulfate (80 mg administered intramuscularly twice a day for 5 to 10 days)
Study: 29660207
Drug: Aripiprazole/sertraline combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole/sertraline combination (ASC)
Study: 29660207
Drug: Placebo/sertraline combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/sertraline combination (PSC)
Study: 27388435
Drug: Lavender aromatherapy
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender aromatherapy (smelled for 20 minutes twice a day over a 12-week period)
Study: 20416130
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplement with meals (SG; n=23; 50 mg Fe as amino acid chelate)
Study: 18582928
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily for 31-39 days (with placebo injection for 10-14 days)
Study: 18582928
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily subcutaneously for 10-14 days (with placebo tablet for 31-39 days)
Study: 12054909
Drug: ozagrel hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ozagrel (DB12017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ozagrel hydrochloride (400 mg for 4 days)
Study: 8382753
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor, lisinopril (ACEI)
Study: 8382753
Drug: Calcium antagonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist, nifedipine (CA)
Study: 28750917
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon (PEG-IFN) therapy
Study: 25318408
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual tablet system (SSTS) dispensing a 15-μg sufentanil tablet sublingually with a 20-minute lockout
Study: 23871270
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (surgery and protraction)
Study: 15496650
Drug: Corydalis yanhusuo
Normalized name: CORYDALIS YANHUSUO TUBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corydalis yanhusuo and Angelicae dahuricae extracts, single oral administration
Study: 7801065
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power Ga-Al-As laser treatment (22.5 joule per treatment, 15 min each, total of nine treatments over 9 weeks)
Study: 3288682
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200-800 micrograms daily)
Study: 3288682
Drug: Budesonide (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200-800 micrograms daily)
Study: 27269205
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral rTMS (600 pulses at 1 Hz followed by 1500 pulses at 10 Hz)
Study: 23638947
Drug: Augmentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation of the mandible with an autologous bone graft followed by placement of four endosseous implants
Study: 23638947
Drug: Short endosseous
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short endosseous implants
Study: 12201973
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (Carmeda or Duraflo)
Study: 12201973
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-heparin-coated circuits)
Study: 9681885
Drug: 8 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 Gy single dose
Study: 9681885
Drug: 5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Gy x4 fractionated dose
Study: 2655366
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 0.5% bupivacaine in 8% glucose (hyperbaric) with 60 min sitting (Group-60)
Study: 2655366
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 0.5% bupivacaine in 8% glucose (hyperbaric) with 2 min sitting (Group-2)
Study: 25580933
Drug: Vigorous exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigorous exercise as a treatment strategy
Study: 14553957
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2 g daily)
Study: 3407868
Drug: Neostigmine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (any dose)
Study: 20494902
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Atorvastatin
Study: 16919926
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcg/day
Study: 16919926
Drug: Oxitropium 800
Normalized name: oxitropium
DrugBank: Oxitropium (DB12086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium 800 mcg/day
Study: 12214543
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement of live Lactobacillus acidophilus and Lactobacillus Casei, 10(7)‐10(8)/ml in fermented milk (LB)
Study: 12214543
Drug: Fluid milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid milk (L) as control
Study: 7710150
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg aerosolized glycopyrrolate
Study: 2651013
Drug: Glycosaminoglycan-peptide complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosaminoglycan-peptide complex (Rumalon), administered as intramuscular injections of 3 x 2 ml ampoules per week for 8 weeks, alternating with 8-week periods free of trial medication
Study: 30859297
Drug: TachoSil® (collagen-fibrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil® (collagen-fibrin sealant patch)
Study: 30859297
Drug: Standard closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard closure without collagen-fibrin sealant patch
Study: 27973336
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (ASA) as post-implantation antithrombotic treatment
Study: 25923820
Drug: Single-Injection (SI)
Normalized name: SIS-101-ADO
DrugBank: SIS-101-ADO (DB18085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Injection (SI)
Study: 25923820
Drug: Triple-Injection (TI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-Injection (TI)
Study: 22129607
Drug: Valsartan +
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + Amlodipine (V‐A) 160/5 mg
Study: 22129607
Drug: Valsartan +
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + Hydrochlorothiazide (V‐H) 160/12.5 mg
Study: 20514078
Drug: Algorithm-guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided dosing for CYP3A5 expressers
Study: 20514078
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing for CYP3A5 nonexpressers
Study: 15243853
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser with dosage of 3 J/per painful point
Study: 15243853
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser with dosage of 1.5 J/per painful point
Study: 11305843
Drug: Generic clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic clozapine (mean daily dose of 630 mg)
Study: 11305843
Drug: Clozaril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozaril (mean daily dose of 610 mg)
Study: 7904847
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (CBS, tetracycline and metronidazole)
Study: 3323596
Drug: Cyclophosphamide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (mean 1.5 mg/kg/day) for 23 +/- 4 months
Study: 15517154
Drug: Modafinil 100
Normalized name: modafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 100 mg
Study: 24177203
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg bid for 16 weeks
Study: 18347003
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment by partial hospitalization
Study: 12405169
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days ceftriaxone therapy
Study: 12405169
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days ceftriaxone therapy
Study: 10375084
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy (CMT) consisting of radiation therapy (RT) and chemotherapy (CT)
Study: 2402811
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia with propofol-fentanyl (Group I)
Study: 2402811
Drug: Propofol-fentanyl anaesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-fentanyl anaesthesia with a supplement of nitrous oxide (Group II)
Study: 7358202
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol and bendrofluazide tablets given twice daily
Study: 7358202
Drug: Combined capsule
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined capsule of propranolol and bendrofluazide given twice daily
Study: 18830236
Drug: Paroxetine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine dose escalation (30-50 mg per day as tolerable)
Study: 18830236
Drug: Placebo dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose escalation (paroxetine 20 mg per day + placebo)
Study: 18830236
Drug: Paroxetine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine dose escalation
Study: 6308063
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (3900 mg per day)
Study: 6308063
Drug: Placebo (Ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Ascorbic acid 1500 mg per day)
Study: 26859491
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (target SBP <140 mmHg)
Study: 26859491
Drug: Guideline-recommended blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended blood pressure treatment (SBP <180 mmHg)
Study: 25147350
Drug: Individually defined,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually defined, targeted physical therapy program
Study: 25147350
Drug: General physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General physical therapy program
Study: 17517480
Drug: Sublingual buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine/naloxone (4/1, 8/2, 16/4, 32mg/8mg)
Study: 17517480
Drug: Split doses
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split doses of buprenorphine/naloxone (50% of the dose that precipitated withdrawal)
Study: 17517480
Drug: Full doses
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full doses of buprenorphine/naloxone (100% of the dose that precipitated withdrawal)
Study: 17517480
Drug: Intramuscular naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular naloxone (0.2mg)
Study: 17517480
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (100mg)
Study: 16387079
Drug: Lipo PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lipo PGE1 therapy
Study: 16387079
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no Lipo PGE1 therapy)
Study: 7619668
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg daily
Study: 7619668
Drug: Inhaled capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled capsaicin
Study: 7619668
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group 1: Long-term enalapril treatment with no cough (n = 18)
Study: 2404072
Drug: Immune DLE
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune DLE (subsequent treatment)
Study: 31723956
Drug: Betacyanin-rich supplement
Normalized name: keracyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betacyanin-rich supplement of Opuntia stricta
Study: 31723956
Drug: Betalain-rich supplement
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betalain-rich supplement of red beetroot
Study: 14599971
Drug: Regular chemotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular chemotherapeutic agents (5‐Fu and MMC)
Study: 10903022
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (PC) 400 mg
Study: 1451519
Drug: Norethisterone 1
Normalized name: Norethisterone 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone 1 mg/ethinyl estradiol 35 micrograms (NET/EE)
Study: 6328298
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg five times daily
Study: 6328298
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg twice daily
Study: 22139613
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injection and panretinal photocoagulation (PRP)
Study: 17414400
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand candidate vaccine (25 microg/dose) administered at 0, 6, and 12 weeks
Study: 17414400
Drug: Norwegian parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norwegian parent vaccine (25 microg/dose) administered at 0, 6, and 12 weeks
Study: 11953964
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Study: 8170449
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and dietary hygiene instructions (Group 1: 492 children)
Study: 8170449
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and dietary hygiene instructions + fluoro-prophylactic treatment (Group 2: 501 children)
Study: 8170449
Drug: No instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: No instructions or treatment (Control Group 3: 482 children)
Study: 2832935
Drug: Thiazide +
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide + unprocessed bran (50 mg b.i.d. from May to September)
Study: 2832935
Drug: Unprocessed bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unprocessed bran (40 g daily)
Study: 20803854
Drug: Crystalloid preload
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid preload anaesthesia (20 mL/kg lactated Ringer's solution)
Study: 16772327
Drug: L-arginine (8.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (8.3 g/day)
Study: 31701610
Drug: Family Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Focused Grief Therapy (FFGT)
Study: 8791240
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg sumatriptan s.c.
Study: 1612732
Drug: Spherule vaccine
Normalized name: Coccidioides immitis spherule
DrugBank: Coccidioides immitis spherule (DB11294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spherule vaccine
Study: 29383698
Drug: Infusion method
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion method TOV
Study: 23331874
Drug: ipulse personal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipulse personal home-use intense pulsed light (IPL) device, treated once weekly for four consecutive weeks
Study: 20847105
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 100 μg/day
Study: 20847105
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 400 μg/day
Study: 20847105
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 1,000 μg/day
Study: 20847105
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2,000 μg/day
Study: 20847105
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation in participants with low serum folate (<4.5 ng/mL)
Study: 18665698
Drug: Psychoeducational Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational Supportive Treatment (PE-SUP)
Study: 10661332
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (ifosfamide, etoposide, high-dose methotrexate, cisplatin, cytarabine)
Study: 10661332
Drug: Immediate postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postoperative radiotherapy with vincristine followed by maintenance chemotherapy (cisplatin, CCNU, vincristine)
Study: 10661332
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (arm I)
Study: 20350693
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous diuretics (IV)
Study: 20350693
Drug: Bolus diuretics
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus diuretics